An anti-IGF-1R antibody, teprotumumab, has recently been shown to be effective in attenuating various TED manifestations in a phase II clinical trial (56), further supporting the potential therapeutic significance of targeting HMGCR in hyperthyroidism. Here, IGF1R is linked to hyperthyroidism.